Peer-Reviewed Publications

      Aerosol filtration testing of fabrics for development of reusable face masks

      Stan, A.; Steiner, S.; Majeed, S.; Schorderet Weber, S.; Gosh, S.; Zivkovic Semren, T.; Guy, P. A.; Lebrun, S.; Steinhauser, J.; Tardy, Y.; Hogg, A.; Chiquet, S.; Perret, J.-L.; Kuczaj, A.; Peitsch, M.; Hoeng, J.
      Published
      May 20, 2021
      DOI
      10.4209/aaqr.210052
      Link to publication
      Topic
      Summary

      The ongoing outbreak of coronavirus disease of 2019 (COVID-19), triggered by the rapid community spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has brought forward the need for speedy testing and manufacturing of respiratory face masks for global use. Overwhelmed by the fast-growing demand for disposable face masks, many governments have recommended the use of, and elaborated design criteria for, reusable face masks that are meant to slow down the transmission of SARS-CoV-2 in the general population. Using aerosol particle size spectrometers, we performed particle size distribution measurements and calculated the fractional aerosol particle size-selective filtration efficiencies of over 300 fabrics and fabric-assemblies, including chiffon, cotton, synthetics, and various promising layered combinations. We suggest, and experimentally verify, a simple way for estimating the aerosol filtration efficiency of layered fabrics. The analysis herein investigates the relationship between the breathability and filtration properties of fabrics, assemblies of fabrics, and commercial reusable masks from various regions around the globe. In addition, we demonstrate how a hydrophobic coating can provide a statistically significant increase in the fabrics’ filtration efficiency. The insights of this work are crucial to developing non-woven, high-filtration-performance, reusable face masks that can be worn for extended periods of time.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.